# An Open-label, Single-arm Study to Evaluate Pharmacokinetics and Safety of Subcutaneous Sonelokimab in Adolescents With Moderate to Severe Hidradenitis Suppurativa (VELA-TEEN)

> **NCT06768671** · PHASE3 · ACTIVE_NOT_RECRUITING · sponsor: **MoonLake Immunotherapeutics AG** · enrollment: 35 (estimated)

## Conditions studied

- Hidradenitis Suppurativa

## Interventions

- **DRUG:** Sonelokimab

## Key facts

- **NCT ID:** NCT06768671
- **Lead sponsor:** MoonLake Immunotherapeutics AG
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2024-12-30
- **Primary completion:** 2026-09-28
- **Final completion:** 2026-09-28
- **Target enrollment:** 35 (ESTIMATED)
- **Last updated:** 2026-05-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06768671

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06768671, "An Open-label, Single-arm Study to Evaluate Pharmacokinetics and Safety of Subcutaneous Sonelokimab in Adolescents With Moderate to Severe Hidradenitis Suppurativa (VELA-TEEN)". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT06768671. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*